Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Boehringer Ingelheim
Medtronic
Harvard Business School
UBS
McKesson
Argus Health
Cipla
Cantor Fitzgerald

Generated: February 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,662,407

« Back to Dashboard

Which drugs does patent 7,662,407 protect, and when does it expire?

Patent 7,662,407 protects APLENZIN and is included in one NDA.

This patent has forty-nine patent family members in seventeen countries.
Summary for Patent: 7,662,407
Title:Modified release formulations of a bupropion salt
Abstract:The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
Inventor(s): Oberegger; Werner (Mississauga, CA), Maes; Paul (Toronto, CA), Jackson; Graham (Co. Kildare, IE), Saleh; Mohammad Ashty (Oakville, CA)
Assignee: Biovail Laboratories International S.R.L. (St. Michael, BB)
Application Number:11/766,251
Patent Claim Types:
see list of patent claims
Composition;

Drugs Protected by US Patent 7,662,407

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Valeant Pharms North APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-001 Apr 23, 2008 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Valeant Pharms North APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-002 Apr 23, 2008 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Valeant Pharms North APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-003 Apr 23, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,662,407

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,354,453 Bupropion hydrobromide and therapeutic applications ➤ Try a Free Trial
7,241,805 Modified release formulations of a bupropion salt ➤ Try a Free Trial
7,569,610 Modified release formulations of a bupropion salt ➤ Try a Free Trial
7,645,802 Bupropion hydrobromide and therapeutic applications ➤ Try a Free Trial
7,884,136 Modified-release formulations of a bupropion salt ➤ Try a Free Trial
7,569,611 Modified release formulations of a bupropion salt ➤ Try a Free Trial
7,579,380 Modified release formulations of a bupropion salt ➤ Try a Free Trial
7,645,901 Modified release formulations of a bupropion salt ➤ Try a Free Trial
7,585,897 Modified release formulations of a bupropion salt ➤ Try a Free Trial
7,572,935 Modified release formulations of a bupropion salt ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,662,407

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2006261788 ➤ Try a Free Trial
Australia 2008285660 ➤ Try a Free Trial
Australia 2008320915 ➤ Try a Free Trial
Canada 2578626 ➤ Try a Free Trial
Canada 2655596 ➤ Try a Free Trial
Canada 2699588 ➤ Try a Free Trial
Canada 2700733 ➤ Try a Free Trial
China 101534808 ➤ Try a Free Trial
China 101784266 ➤ Try a Free Trial
China 101903016 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Chinese Patent Office
McKinsey
Fuji
Julphar
Citi
US Army
Accenture
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot